Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study
- 1 April 1998
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (5) , 754-756
- https://doi.org/10.1016/s0959-8049(97)10089-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Immunomodulatory and Hematopoietic Effects of Recombinant Human Interleukin-6 in Patients with Advanced Renal Cell CancerJournal of Interferon & Cytokine Research, 1996
- Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trialBritish Journal of Cancer, 1996
- Endocrine Effects of Recombinant Interleukin 6 in ManNeuroendocrinology, 1996
- gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells.Proceedings of the National Academy of Sciences, 1995
- Effects of recombinant human interleukin-6 in cancer patients: a phase I-II studyBlood, 1994
- Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55Blood, 1994
- Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.Journal of Clinical Oncology, 1993
- Spontaneous Regression of Histologically Proved Pulmonary Metastases from Renal Cell Carcinoma: A Case with 5-Year FollowupJournal of Urology, 1992
- Interleukin 6 is a differentiation factor for human megakaryocytes in vitroEuropean Journal of Immunology, 1990
- Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.Proceedings of the National Academy of Sciences, 1987